TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37994980

Group type: EXPERIMENTAL
Intervention: Iohexol plasma clearance (CL)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: eGFR above age-specific thresholds
Number of subjects: 85
Study: 37994989

Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 1 g/day for 10 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 37995070

Group type: EXPERIMENTAL
Intervention: Molnupiravir (800 mg every 12 hours for 5 days)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 37995129

Group type: EXPERIMENTAL
Intervention: SAFE program
Number of subjects: 115

Group type: COMPARATOR
Intervention: MBCC
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 115
Study: 37995325

Group type: EXPERIMENTAL
Intervention: BMC+β-TCP
Number of subjects: 94

Group type: COMPARATOR
Intervention: β-TCP only
Number of subjects: 94
Study: 37995381

Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx)
Number of subjects: 9
Study: 37995506

Group type: EXPERIMENTAL
Intervention: Dissolve DCB
Number of subjects: 247

Group type: COMPARATOR
Intervention: Resolute DES
Number of subjects: 247
Study: 37995609

Group type: EXPERIMENTAL
Intervention: Intraoperative frontal EEG monitoring during Isoflurane effect-site concentrations of 0.7 to 0.8
Number of subjects: 828

Group type: COMPARATOR
Intervention: Control group (non-POD)
Number of subjects: 828
Study: 37995847

Group type: EXPERIMENTAL
Intervention: ELF scores
Number of subjects: 136
Study: 37995967

Group type: EXPERIMENTAL
Intervention: DiabeText messaging intervention
Number of subjects: 740

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 740
Study: 37996071

Group type: EXPERIMENTAL
Intervention: Variant-specific IgA antibody response at 1 month after booster vaccination
Number of subjects: 2

Group type: COMPARATOR
Intervention: Infection status (Infected vs Uninfected)
Number of subjects: 2
Study: 37996099

Group type: EXPERIMENTAL
Intervention: Higher Nicotine Metabolite Ratio (NMR)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Cigarette trials
Number of subjects: 252

Group type: COMPARATOR
Intervention: Water trials
Number of subjects: 252
Study: 37996121

Group type: EXPERIMENTAL
Intervention: Short-term exercise prehabilitation programme
Number of subjects: 12
Study: 37996236

Group type: EXPERIMENTAL
Intervention: Stepped and collaborative care model (SCCM) with screening and psychosomatic-psychiatric consultations for distressed patients (phase II)
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) with screening but without consequences (phase I, main comparator)
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) without screening for distress (phase 0)
Number of subjects: 2200
Study: 37996238

Group type: EXPERIMENTAL
Intervention: Extended ECG monitoring (14+14 days of continuous ECG monitoring 3 months apart using an ECG patch device)
Number of subjects: 3262

Group type: COMPARATOR
Intervention: Standard ECG monitoring (48±24 hours of continuous ECG monitoring)
Number of subjects: 3262
Study: 37996266

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PC)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VC)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 372
Study: 37996507

Group type: EXPERIMENTAL
Intervention: FOLFOX/bevacizumab + irinotecan
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFOX/bevacizumab
Number of subjects: 0
Study: 37996557

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz, 3000 pulses per session)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 42
Study: 37996653

Group type: EXPERIMENTAL
Intervention: Isoliquiritigenin (ISO)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Combination of ISO with visceral adipose tissue (VAT) and other NAFLD-related variables
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Lower levels of ISO
Number of subjects: 143
Study: 37996787

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0 µg/kg) in Group A-Y
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0 µg/kg) in Group A-O
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 µg/kg) in Group B
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg/kg) in Group C
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 µg/kg)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg/kg)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate (RT)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control (no Dexmedetomidine)
Number of subjects: 114
Study: 37996817

Group type: EXPERIMENTAL
Intervention: AD16 5 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: AD16 10 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: AD16 20 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: AD16 30 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: AD16 40 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: AD16 60 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: AD16 80 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: AD16 20 mg under fasted condition
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: AD16 20 mg under fed condition
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 37996898

Group type: EXPERIMENTAL
Intervention: Thoracic epidural blockade (TEB)
Number of subjects: 1026

Group type: COMPARATOR
Intervention: Paravertebral blockade (PVB)
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: TEB
Number of subjects: 1026

Group type: COMPARATOR
Intervention: PVB
Number of subjects: 1026
Study: 37996906

Group type: EXPERIMENTAL
Intervention: High-power short-duration (HPSD) ablation using Smart Touch Surround Flow (STSF) catheter (power set at 50 W)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional ablation using Smart Touch (ST) catheter (power set at 30 to 35 W)
Number of subjects: 100
Study: 37996955

Group type: EXPERIMENTAL
Intervention: Sentinel CPS during LAAC
Number of subjects: 240

Group type: COMPARATOR
Intervention: LAAC without Sentinel CPS
Number of subjects: 240
Study: 37997056

Group type: EXPERIMENTAL
Intervention: behavSMS
Number of subjects: 9027

Group type: EXPERIMENTAL
Intervention: behavSMS+video
Number of subjects: 9027

Group type: COMPARATOR
Intervention: Control
Number of subjects: 9027
Study: 37997062

Group type: EXPERIMENTAL
Intervention: Letter informing GP practices of the PLEASANT trial results
Number of subjects: 90583

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 90583

Group type: COMPARATOR
Intervention: Overall comparison
Number of subjects: 90583
Study: 37997387

Group type: EXPERIMENTAL
Intervention: Brief dialectical behavior therapy (DBT)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Pre-treatment cognitive performance
Number of subjects: 240
Study: 37997684

Group type: EXPERIMENTAL
Intervention: WeFlow-JAAA endograft system
Number of subjects: 15
Study: 37997749

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 75
Study: 37997800

Group type: EXPERIMENTAL
Intervention: ACBMNCs infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angptl7 treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: LPS group
Number of subjects: 0
Study: 37999656

Group type: EXPERIMENTAL
Intervention: PET myocardial blood flow (MBF) quantification at 12 months post-transplant
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Endomyocardial biopsy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound examination
Number of subjects: 74
Study: 37999672

Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation (tVNS) at 20 Hz, 1 mA below discomfort threshold, delivered for 1 hour daily over 2 months.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham stimulation (ear lobe), n = 14.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation (tVNS)
Number of subjects: 26
Study: 37999708

Group type: EXPERIMENTAL
Intervention: HighLife Trans-Septal Mitral Valve Replacement (TSMVR) system
Number of subjects: 30
Study: 37999854

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy plus placebo followed by adjuvant placebo
Number of subjects: 0
Study: 37999936

Group type: EXPERIMENTAL
Intervention: PROXY (8-week psychological internet-delivered treatment)
Number of subjects: 5
Study: 37999939

Group type: EXPERIMENTAL
Intervention: Perampanel (PER) 4 mg per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1000 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel (PER)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 0
Study: 37999953

Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using the Internet (SHUTi)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Insomnia Education Website (IEW)
Number of subjects: 231
Study: 37999958

Group type: EXPERIMENTAL
Intervention: ChatGPT (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard web-based tools (group B)
Number of subjects: 50
Study: 37999982

Group type: EXPERIMENTAL
Intervention: Anticholinergic burden assessed using the Anticholinergic Cognitive Burden scale (ACB) and Drug Burden Index (DBI) scale
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Deprescribing approach
Number of subjects: 255
Study: 38000051

Group type: EXPERIMENTAL
Intervention: Minimally invasive mastectomy group
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional mastectomy group
Number of subjects: 63
Study: 38000061

Group type: EXPERIMENTAL
Intervention: RM score ≥ 100
Number of subjects: 40

Group type: COMPARATOR
Intervention: RM score < 100
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall cohort with RM score ≥ 100
Number of subjects: 40

Group type: COMPARATOR
Intervention: Overall cohort with RM score < 100
Number of subjects: 40
Study: 38000068

Group type: EXPERIMENTAL
Intervention: ClassIntra
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Kaafarani
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: SAS
Number of subjects: 755
Study: 38000074

Group type: EXPERIMENTAL
Intervention: wTN staging model based on T stage and N stage weights
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: wTN staging model
Number of subjects: 0
Study: 38000343

Group type: EXPERIMENTAL
Intervention: Low-intensity chemotherapy (n=53), Intensive chemotherapy (n=6)
Number of subjects: 59
Study: 38000564

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 38000696

Group type: EXPERIMENTAL
Intervention: Multiethnic Black (ME/B) participants
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Puerto Rican Black Latinx participants
Number of subjects: 744

Group type: COMPARATOR
Intervention: African American (AA/B) participants
Number of subjects: 744
Study: 38000815

Group type: EXPERIMENTAL
Intervention: Potassium intake measured by 24-hour urinary potassium in individuals with moderate risk of hyperkalaemia.
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Potassium intake measured by 24-hour urinary potassium in individuals with high risk of hyperkalaemia.
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Potassium intake measured by 24-hour urinary potassium in individuals with low risk of hyperkalaemia.
Number of subjects: 962
Study: 38000818

Group type: EXPERIMENTAL
Intervention: RUTF with 5% rice bran
Number of subjects: 200

Group type: COMPARATOR
Intervention: Locally produced RUTF (active control)
Number of subjects: 200
Study: 38000822

Group type: EXPERIMENTAL
Intervention: Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IC3 assessment integrated within a larger prospective observational longitudinal clinical trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IC3 assessment
Number of subjects: 0
Study: 38000826

Group type: EXPERIMENTAL
Intervention: Short-cohort study involving repeat testing of child faeces for enteric pathogens.
Number of subjects: 0
Study: 38000871

Group type: EXPERIMENTAL
Intervention: Drone-delivered AED
Number of subjects: 211
Study: 38000996

Group type: EXPERIMENTAL
Intervention: High waist circumference group
Number of subjects: 80
Study: 38001050

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin (hs-cTn) assays
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: hs-cTn-based strategies
Number of subjects: 238
Study: 38001145

Group type: EXPERIMENTAL
Intervention: Weight loss prediction models using six machine learning methods
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Logistic regression modeling approach
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Web application for weight change prediction
Number of subjects: 327
Study: 38001232

Group type: EXPERIMENTAL
Intervention: Customized hip braces based on 3D scanner measurements worn for 7 days
Number of subjects: 19
Study: 38001309

Group type: EXPERIMENTAL
Intervention: Sleep time (hours/day)
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Hepatic steatosis index
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Body fat distribution
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Lifestyle markers
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Sleep time
Number of subjects: 854
Study: 38001310

Group type: EXPERIMENTAL
Intervention: High-resolution T1 MRI data analyzed with FreeSurfer software
Number of subjects: 50
Study: 38001403

Group type: EXPERIMENTAL
Intervention: Interpersonal relationships (positive and negative experiences)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Conceptual model of interplay between suicidal experiences, psychosis, and interpersonal relationships
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Themes of interpersonal relationship dynamics
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Insights into interpersonal relationships and suicidal experiences
Number of subjects: 22
Study: 38001461

Group type: EXPERIMENTAL
Intervention: Hand reflexology
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 38001469

Group type: EXPERIMENTAL
Intervention: Tuberculosis (TB)
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Non-tuberculosis mycobacterium (NTM) infection
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Latent tuberculosis infection (LTBI)
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: N-acetyltransferase-2 (NAT2) phenotypes in TB
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: N-acetyltransferase-2 (NAT2) phenotypes in NTM
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: N-acetyltransferase-2 (NAT2) phenotypes in LTBI
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: SLCO1B1 phenotypes in TB
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: SLCO1B1 phenotypes in NTM
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: SLCO1B1 phenotypes in LTBI
Number of subjects: 1226
Study: 38001473

Group type: EXPERIMENTAL
Intervention: Evaluative conditioning training with real tDCS over the orbitofrontal cortex
Number of subjects: 55

Group type: COMPARATOR
Intervention: Evaluative conditioning training with sham tDCS over the orbitofrontal cortex
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham evaluative conditioning training with real tDCS over the orbitofrontal cortex
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham evaluative conditioning training with sham tDCS over the orbitofrontal cortex
Number of subjects: 55
Study: 38001474

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1000 mg fish oil, 13% EPA, 9% DHA) with glimepiride 3 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (corn oil and linoleic acid) with glimepiride 3 mg
Number of subjects: 70
Study: 38001478

Group type: EXPERIMENTAL
Intervention: IAU + EBIS
Number of subjects: 40

Group type: COMPARATOR
Intervention: IAU
Number of subjects: 40
Study: 38001506

Group type: EXPERIMENTAL
Intervention: Nudges to patients
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Nudges to clinicians
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Nudges to both patients and clinicians
Number of subjects: 1600

Group type: COMPARATOR
Intervention: No nudges (neither)
Number of subjects: 1600
Study: 38001507

Group type: EXPERIMENTAL
Intervention: Limiting ED rocuronium exposure (using succinylcholine as the default NMB)
Number of subjects: 3090

Group type: COMPARATOR
Intervention: Control phase (observational conditions with rocuronium)
Number of subjects: 3090

Group type: EXPERIMENTAL
Intervention: Intervention phase (using succinylcholine as the default NMB)
Number of subjects: 3090

Group type: EXPERIMENTAL
Intervention: Intervention phase
Number of subjects: 3090
Study: 38001523

Group type: EXPERIMENTAL
Intervention: CARE-CITE-Gait intervention (4-week duration, includes online video-based modules and two 2-hour home visits)
Number of subjects: 15
Study: 38001540

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (VR) combined with standard early mobilization protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard early mobilization protocol (Control)
Number of subjects: 0
Study: 38001544

Group type: EXPERIMENTAL
Intervention: Virtually delivered Body Project groups led by clinicians
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Virtually delivered Body Project groups led by peers
Number of subjects: 441

Group type: COMPARATOR
Intervention: Psychoeducational control group
Number of subjects: 441
Study: 38001951

Group type: EXPERIMENTAL
Intervention: Mild water-filtered infrared-A whole-body hyperthermia (wIRA-WBH)
Number of subjects: 0
Study: 38002616

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine added to Bupivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tramadol added to Bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine alone (Control)
Number of subjects: 0
Study: 38002635

Group type: EXPERIMENTAL
Intervention: Twice-weekly thirty-minute exercise intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 73
Study: 38004228

Group type: EXPERIMENTAL
Intervention: Carnosine 2 g/day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 38004269

Group type: EXPERIMENTAL
Intervention: Front-crawl swimming task
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: EMG metrics for 12 muscles
Number of subjects: 21
Study: 38004546

Group type: EXPERIMENTAL
Intervention: New food-grade berberine delivery system (Berberine LipoMicel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard berberine formulation
Number of subjects: 0
Study: 38006001

Group type: EXPERIMENTAL
Intervention: BNT162b2 (vaccinated group)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Unvaccinated/not up-to-date (control group)
Number of subjects: 643
Study: 38006237

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 53

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 53
Study: 38006892

Group type: EXPERIMENTAL
Intervention: VV116 (0·6 g every 12 h on day 1 and 0·3 g every 12 h on days 2-5)
Number of subjects: 1347

Group type: COMPARATOR
Intervention: Placebo (on the same schedule as VV116)
Number of subjects: 1347
Study: 38006908

Group type: EXPERIMENTAL
Intervention: Intensive therapy targeting systolic BP <130 mm Hg
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard therapy targeting systolic BP <140 mm Hg
Number of subjects: 128
Study: 38006967

Group type: EXPERIMENTAL
Intervention: Early target temperature (TT) group (≤4 hours of age)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Late target temperature (TT) group (>4 hours of age)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Early TT group (≤4 hours of age)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Late TT group (>4 hours of age)
Number of subjects: 500
Study: 38006972

Group type: EXPERIMENTAL
Intervention: Berotralstat 150 mg once-daily monotherapy
Number of subjects: 34
Study: 38007219

Group type: EXPERIMENTAL
Intervention: First-line cryoablation
Number of subjects: 3
Study: 38007349

Group type: EXPERIMENTAL
Intervention: First-line trastuzumab with pertuzumab
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: First-line trastuzumab without pertuzumab
Number of subjects: 225

Group type: COMPARATOR
Intervention: Trastuzumab pretreated patients
Number of subjects: 225
Study: 38007586

Group type: EXPERIMENTAL
Intervention: Bosutinib (starting dose: 500 mg/day)
Number of subjects: 156
Study: 38007646

Group type: EXPERIMENTAL
Intervention: Gustatory evoked potentials (GEPs) in response to sucrose solution
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cognitive assessments and hormone levels (ghrelin, leptin, insulin, serotonin)
Number of subjects: 45
Study: 38007648

Group type: EXPERIMENTAL
Intervention: Nordic Sensi® Chair (NSC) - 20 minutes per session, three times a week for 16 weeks
Number of subjects: 77
Study: 38008001

Group type: EXPERIMENTAL
Intervention: LAMA2-MD
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: SELENON-RM
Number of subjects: 37

Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: SNIP
Number of subjects: 37
Study: 38008031

Group type: EXPERIMENTAL
Intervention: Belzutifan 120 mg orally once daily until disease progression, unacceptable toxicity, or patient withdrawal.
Number of subjects: 55
Study: 38008033

Group type: EXPERIMENTAL
Intervention: Consolidating high-dose therapy and autologous hematopoietic stem cell transplantation (HDT-ASCT) in partial response (PR) or better
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Cohort I (synchronous SCNSL)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Cohort II (metachronous SCNSL)
Number of subjects: 243
Study: 38008099

Group type: EXPERIMENTAL
Intervention: Rezafungin (400 mg and 200 mg once-a-week intravenous)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Caspofungin (70 mg and 50 mg once-a-day intravenous)
Number of subjects: 294